sulbactam-durlobactam
NDA- Indications
- Acinetobacter baumannii infections
Company intelligence / Profile preview
Entasis Therapeutics
Waltham, Massachusetts, United Statesleadiq.com ↗
- Ownership
- Public · INVA
- Employees
- ~53
- Development stage
- NDA
01
Overview
Entasis has a pipeline of clinical and preclinical antibacterial programs targeting serious drug-resistant bacterial infections. Their lead candidate SUL-DUR (sulbactam-durlobactam) is for treating pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii[3][5].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculesantibacterial products
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $1.6B
- Total revenue
- $119.6M
- Enterprise value
- $1.3B
Beyond the preview
Go deeper on Entasis Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Entasis Therapeutics.